reported that GPR64 was encapsulated in exosomes and released into the tumor microenvironment, enhancing the invasive and metastatic abilities of cancer cells by activating the NF-κB-pathway and upregulating the levels of MMP9 and IL - 8 (50). This evidence concerns the gene NFKB1 and neoplasm.